Role of raloxifene as a potent inhibitor of experimental postmenopausal polyarthritis and osteoporosis

Arthritis and Rheumatism

Volumn 56, Issue 10, 2007, Pages 3261-3270

  Jochems, Caroline ^a   Islander, Ulrika ^a   Kallkopf, Anna ^a   Lagerquist, Marie ^a   Ohlsson, Claes ^a   Carlsten, Hans ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

6 HYDROXY 2 (4 HYDROXYPHENYL) 3 [4 [2 (1 PYRROLIDINYL)ETHOXY]BENZOYL]BENZO[B]THIOPHENE; CYTOKINE; ESTRADIOL BENZOATE; MATRIX PROTEIN; MESSENGER RNA; OSTEOCLAST DIFFERENTIATION FACTOR; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DENSITY; BONE TURNOVER; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DBA 1 MOUSE; ESTROGEN DEFICIENCY; FEMALE; HORMONE SUBSTITUTION; INFLAMMATORY DISEASE; MOUSE; NONHUMAN; OVARIECTOMY; POLYARTHRITIS; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RHEUMATOID ARTHRITIS; SPLEEN CELL;

ANIMALS; ARTHRITIS; ARTHRITIS, EXPERIMENTAL; BONE DENSITY; CYTOKINES; FEMALE; HUMANS; MICE; OSTEOPOROSIS, POSTMENOPAUSAL; POSTMENOPAUSE; PYRROLIDINES; RALOXIFENE; RANK LIGAND; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SELECTIVE ESTROGEN RECEPTOR MODULATORS; THIOPHENES; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 35348922481     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.22873     Document Type: Article

References (36)

1. Doran MF, Pond GR, Crowson CS, O'Fallon WM, Gabriel SE. Trends in incidence and mortality in rheumatoid arthritis in Rochester, Minnesota, over a forty-year period. Arthritis Rheum 2002;46:625-31.
2. Goemaere S, Ackerman C, Goethals K, De Keyser F, Van der Straeten C, Verbruggen G, et al. Onset of symptoms of rheumatoid arthritis in relation to age, sex and menopausal transition. J Rheumatol 1990;17:1620-2.
3. Forsblad D'Elia H, Larsen A, Mattsson LA, Waltbrand E, Kvist G, Mellstrom D, et al. Influence of hormone replacement therapy on disease progression and bone mineral density in rheumatoid arthritis. J Rheumatol 2003;30:1456-63.
4. Ostensen M, Aune B, Husby G. Effect of pregnancy and hormonal changes on the activity of rheumatoid arthritis. Scand J Rheumatol 1983;12:69-72.
5. Holmdahl R, Jansson L, Andersson M. Female sex hormones suppress development of collagen-induced arthritis in mice. Arthritis Rheum 1986;29:1501-9.
6. Jansson L, Holmdahl R. Oestrogen induced suppression of collagen arthritis. IV. Progesterone alone does not affect the course of arthritis but enhances the oestrogen-mediated therapeutic effect. J Reprod Immunol 1989;15:141-50.
7. Yamasaki D, Enokida M, Okano T, Hagino H, Teshima R. Effects of ovariectomy and estrogen replacement therapy on arthritis and bone mineral density in rats with collagen-induced arthritis. Bone 2001;28:634-40.
8. Doran MF, Crowson CS, O'Fallon WM, Gabriel SE. The effect of oral contraceptives and estrogen replacement therapy on the risk of rheumatoid arthritis: a population based study. J Rheumatol 2004;31:207-13.
9. Forsblad D'Elia H, Larsen A, Waltbrand E, Kvist G, Mellstrom D, Saxne T, et al. Radiographic joint destruction in postmenopausal rheumatoid arthritis is strongly associated with generalised osteoporosis. Ann Rheum Dis 2003;62:617-23.
10. Sinigaglia L, Nervetti A, Mela Q, Bianchi G, Del Puente A, Di Munno O, et al, for the Italian Study Group on Bone Mass in Rheumatoid Arthritis. A multicenter cross sectional study on bone mineral density in rheumatoid arthritis. J Rheumatol 2000;27:2582-9.
11. Holmdahl R, Bockermann R, Backlund J, Yamada H. The molecular pathogenesis of collagen-induced arthritis in mice: a model for rheumatoid arthritis. Ageing Res Rev 2002;1:135-47.
12. Jansson L, Holmdahl R. Estrogen-mediated immunosuppression in autoimmune diseases. Inflamm Res 1998;47:290-301.
13. Jansson L, Holmdahl R. Enhancement of collagen-induced arthritis in female mice by estrogen receptor blockage. Arthritis Rheum 2001;44:2168-75.
14. Jochems C, Islander U, Erlandsson M, Verdrengh M, Ohlsson C, Carlsten H. Osteoporosis in experimental postmenopausal polyarthritis: the relative contributions of estrogen deficiency and inflammation. Arthritis Res Ther 2005;7:R837-43.
15. Stefanick ML. Estrogens and progestins: background and history, trends in use, and guidelines and regimens approved by the US Food and Drug Administration. Am J Med 2005;118:64-73.
16. Li X, Takahashi M, Kushida K, Inoue T. The preventive and interventional effects of raloxifene analog (LY117018 HCL) on osteopenia in ovariectomized rats. J Bone Miner Res 1998;13:1005-10.
17. Sato M, Kim J, Short LL, Slemenda CW, Bryant HU. Longitudinal and cross-sectional analysis of raloxifene effects on tibiae from ovariectomized aged rats. J Pharmacol Exp Ther 1995;272:1252-9.
18. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, et al, for the Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial [published erratum in JAMA 1999;282:2124]. JAMA 1999;282:637-45.
19. Sato M, Rippy MK, Bryant HU. Raloxifene, tamoxifen, nafoxidine, or estrogen effects on reproductive and nonreproductive tissues in ovariectomized rats. FASEB J 1996;10:905-12.
20. Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. JAMA 1999;281:2189-97.
21. Holmdahl R, Jansson L, Larsson E, Rubin K, Klareskog L Homologous type II collagen induces chronic and progressive arthritis in mice. Arthritis Rheum 1986;29:106-13.
22. Erlandsson MC, Gomori E, Taube M, Carlsten H. Effects of raloxifene, a selective estrogen receptor modulator, on thymus, T cell reactivity, and inflammation in mice. Cell Immunol 2000;205:103-9.
23. Erlandsson MC, Jonsson CA, Lindberg MK, Ohlsson C, Carlsten H. Raloxifene- and estradiol-mediated effects on uterus, bone and B lymphocytes in mice. J Endocrinol 2002;175:319-27.
24. Onoe Y, Miyaura C, Ito M, Ohta H, Nozawa S, Suda T. Comparative effects of estrogen and raloxifene on B lymphopoiesis and bone loss induced by sex steroid deficiency in mice. J Bone Miner Res 2000;15:541-9.
25. Helle M, Boeije L, Aarden LA. Functional discrimination between interleukin 6 and interleukin 1. Eur J Immunol 1988;18:1535-40.
26. -/- mice. J Clin Invest 1999;104:895-901.
27. Guiducci S, Del Rosso A, Cinelli M, Perfetto F, Livi R, Rossi A, et al. Raloxifene reduces urokinase-type plasminogen activator-dependent proliferation of synoviocytes from patients with rheumatoid arthritis. Arthritis Res Ther 2005;7:R1244-53.
28. Wooley PH, Luthra HS, Stuart JM, David CS. Type II collagen-induced arthritis in mice. I. Major histocompatibility complex (I region) linkage and antibody correlates. J Exp Med 1981;154:688-700.
29. Esposito E, Iacono A, Raso GM, Pacilio M, Coppola A, Di Carlo R, et al. Raloxifene, a selective estrogen receptor modulator, reduces carrageenan-induced acute inflammation in normal and ovariectomized rats. Endocrinology 2005;146:3301-8.
30. Badger AM, Blake SM, Dodds RA, Griswold DE, Swift BA, Rieman DJ, et al. Idoxifene, a novel selective estrogen receptor modulator, is effective in a rat model of adjuvant-induced arthritis. J Pharmacol Exp Ther 1999;291:1380-6.
31. Reginster JY, Sarkar S, Zegels B, Henrotin Y, Bruyere O, Agnusdei D, et al. Reduction in PINP, a marker of bone metabolism, with raloxifene treatment and its relationship with vertebral fracture risk. Bone 2004;34:344-51.
32. Gianni W, Ricci A, Gazzaniga P, Brama M, Pietropaolo M, Votano S, et al. Raloxifene modulates interleukin-6 and tumor necrosis factor-α synthesis in vivo: results from a pilot clinical study. J Clin Endocrinol Metab 2004;89:6097-9.
33. Viereck V, Grundker C, Blaschke S, Niederkleine B, Siggelkow H, Frosch KH, et al. Raloxifene concurrently stimulates osteoprotegerin and inhibits interleukin-6 production by human trabecular osteoblasts. J Clin Endocrinol Metab 2003;88:4206-13.
34. Keith JC Jr, Albert LM, Leathurby Y, Follettie M, Wang L, Borges-Marcucci L, et al. The utility of pathway selective estrogen receptor ligands that inhibit nuclear factor-κB transcriptional activity in models of rheumatoid arthritis. Arthritis Res Ther 2005;7:R427-38.
35. Barrett-Connor E, Mosca L, Collins P, Geiger MJ, Grady D, KornitzEr M, et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 2006;355:125-37.
36. Christodoulakos GE, Botsis DS, Lambrinoudaki IV, Papagianni VD, Panoulis CP, Creatsa MG, et al. A 5-year study on the effect of hormone therapy, tibolone and raloxifene on vaginal bleeding and endometrial thickness. Maturitas 2006;53:413-23.